{"nctId":"NCT00765895","briefTitle":"Nortriptyline for Idiopathic Gastroparesis","startDateStruct":{"date":"2009-01","type":"ACTUAL"},"conditions":["Idiopathic Gastroparesis"],"count":130,"armGroups":[{"label":"Nortriptyline","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: Nortriptyline Hydrochloride"]},{"label":"Placebo (for nortriptyline)","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: Placebo (for nortriptyline)"]}],"interventions":[{"name":"Nortriptyline Hydrochloride","otherNames":["Nortriptyline HCl","Pamelor"]},{"name":"Placebo (for nortriptyline)","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Age 21 through 65 years old at registration\n* Documentation of delayed gastric emptying on gastric emptying scintigraphy within 2 years of registration, defined as greater than 60% retention at 2 hours or greater than 10% retention at 4 hours\n* Symptoms of gastroparesis for at least 6 months (does not have to be contiguous) prior to registration with Gastroparesis Cardinal Symptom Index (GCSI) score of 21 or greater\n* Negative upper endoscopy or upper GI series within 2 years of registration\n\nExclusion Criteria:\n\n* Normal gastric emptying confirmed with scintigraphy\n* Diabetic gastroparesis or post-surgical gastroparesis including fundoplication\n* Another active disorder which could explain symptoms in the opinion of the investigator\n* History of significant cardiac arrhythmias and/or prolonged QTc\n* History of seizures\n* Use of narcotics more than 3 days per week\n* Use of tricyclic antidepressants for refractory symptoms of gastroparesis within 6 weeks prior to randomization\n* Use of strongly anticholinergic medications\n* Use of calcium channel blockers\n* Use of erythromycin\n* Clear history of failed trial of nortriptyline use for gastroparetic symptoms\n* Symptoms of primary depression or suicidal ideation\n* Contraindications to nortriptyline:\n\n  1. hypersensitivity or allergy to any tricyclic antidepressant drug\n  2. concomitant therapy with a monoamine oxidase inhibitor (MAOI)\n  3. recent myocardial infarction\n  4. glaucoma\n* Pregnancy or nursing\n* Any other condition, which in the opinion of the investigator would impede compliance or hinder completion of the study\n* Use of a G tube, J tube,or a central catheter for nutrition\n* Use of a gastric electrical stimulator\n* Failure to give informed consent","healthyVolunteers":false,"sex":"ALL","minimumAge":"21 Years","maximumAge":"65 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Decrease From the Baseline GCSI of at Least 50% on Any Two Consecutive Follow-up Visits","description":"A decrease from the baseline Gastroparesis Cardinal Symptom Index (GCSI) score (sum of the 9 individual symptom scores) of at least 50% on any two consecutive follow-up visits during the 15 week treatment period with maximum tolerated study drug dose. The total score ranges from 0-45 with higher scores indicating greater symptom severity.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"15","spread":null},{"groupId":"OG001","value":"14","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":5,"n":65},"commonTop":["cardiac","gastrointestinal events","Nervous system","renal and urinary events","psychiatric"]}}}